Latest Regulation News

Page 19 of 166
The Fonterra Shareholders’ Fund reported a 38% FY26 total unit-holder return, supported by a $2.73 per-unit cash distribution after Fonterra’s Mainland divestment. Reported revenue fell 27% to NZ$287 million, reflecting the Fund’s passive structure and fair-value accounting rather than an operating loss.
Ada Torres
Ada Torres
24 Sept 2026
Resource Minerals International has expanded its exploration push across Tanzania and Saudi Arabia, but auditors flagged a material uncertainty over the company’s ability to continue without future capital raisings. The ASX-listed explorer ended FY2026 with $2.12 million in cash after raising funds through placements and convertible securities.
Maxwell Dee
Maxwell Dee
23 Sept 2026
West Cobar Metals has engaged Wallis Drilling for its first scandium-focused campaign at the Salazar project, with work targeted for October subject to approvals. The programme will test shallow saprolite for higher-grade scandium zones and extensions to existing rare earth and titanium dioxide resources.
Maxwell Dee
Maxwell Dee
23 Sept 2026
Southern Cross Gold’s Sunday Creek project has cleared its first formal mining licence hurdle, with Resources Victoria accepting a 30.7-hectare application covering the Golden Dyke workings. The milestone begins a public assessment process, but does not yet authorise mining.
Maxwell Dee
Maxwell Dee
23 Sept 2026
Global Lithium’s proposed acquisition of the Nova Operation from IGO has become unconditional after the ACCC waived its notification requirement. Completion is still pending the shutdown and final shipment timetable, with the transaction not yet completed.
Maxwell Dee
Maxwell Dee
23 Sept 2026
Tuas Limited (ASX:TUA) delivered a sharp FY2026 earnings lift as Simba’s mobile and broadband subscriber base expanded, with statutory profit rising 277% to S$26.0 million. The result arrives with the M1 acquisition abandoned, S$364.5 million raised but not yet allocated, and an unresolved Singapore spectrum investigation.
Sophie Babbage
Sophie Babbage
23 Sept 2026
Eminence Minerals has begun field exploration across three pending licence applications at its Tayra rare earth project in Bahia, Brazil, while continuing a planned 70-hole auger campaign at Campo Grande. The work remains early-stage, with no Mineral Resource defined and Tayra’s tenure still awaiting confirmation from Brazil’s mining regulator.
Maxwell Dee
Maxwell Dee
23 Sept 2026
AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.
Ada Torres
Ada Torres
23 Sept 2026
Zeus Resources has completed due diligence on its Diaguili copper-gold project in southern Mauritania after regulators validated the environmental notice for exploration. The company will now proceed to the first completion stage of the acquisition, with historical drilling providing the project’s main technical attraction but also its principal qualification.
Maxwell Dee
Maxwell Dee
23 Sept 2026
Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.
Ada Torres
Ada Torres
22 Sept 2026
OD6 Metals has transformed its portfolio with the completed acquisition of Nevada’s Quinn Fluorspar Project, but the strategic expansion comes alongside a larger loss, ongoing funding needs and substantial permitting risk. The company is now targeting drilling and a maiden resource at Quinn while advancing laboratory-scale rare earth processing work at Splinter Rock.
Maxwell Dee
Maxwell Dee
21 Sept 2026
AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.
Ada Torres
Ada Torres
18 Sept 2026

Browse the archive

Full archive